Table 2

Associations of Regimens of HRT use with prognostic factors

VariableUsed ERTaUsed S-CHRTcUsed C-CHRTd
ORb(95% CI)ORb(95% CI)ORb(95% CI)
Histology
 Ductal1.0Ref.e1.0Ref.1.0Ref.
 Any lobular1.20.9–1.71.30.9–1.91.71.2–2.4
 All other1.30.9–1.81.40.9–2.00.90.6–1.5
Tumor size
 <2 cm1.0Ref.1.0Ref.1.0Ref.
 2 to <5 cm0.70.6–0.90.80.6–1.00.70.5–1.0
 5+ cm0.60.4–0.90.50.3–0.80.40.2–0.7
Tumor sizef
 <2 cm1.0Ref.1.0Ref.1.0Ref.
 2 to <5 cm1.00.7–1.21.10.8–1.51.00.7–1.4
 5+ cm0.90.6–1.40.90.5–1.70.70.4–1.3
Stage
 Local1.0Ref.1.0Ref.1.0Ref.
 Regional/distant0.60.5–0.80.60.5–0.80.70.5–0.9
Stagef
 Local1.0Ref.1.0Ref.1.0Ref.
 Regional/distant0.70.6–0.90.80.6–1.10.90.6–1.2
ER/PR status
 ER+1.0Ref.1.0Ref.1.0Ref.
 ER−1.00.7–1.20.80.6–1.20.60.4–0.9
 PR+1.0Ref.1.0Ref.1.0Ref.
 PR−1.00.8–1.31.00.7–1.30.50.4–0.7
 ER+/PR+1.0Ref.1.0Ref.1.0Ref.
 ER+/PR−1.00.7–1.51.40.9–2.20.60.4–1.0g
 ER−/PR+1.10.6–2.01.50.7–2.91.20.6–2.5
 ER−/PR−1.00.7–1.30.80.6–1.20.50.3–0.8
  • a ERT, unopposed estrogen.

  • b Relative to never users of HRT and adjusted for age, race, and study site.

  • c S-CHRT, sequential estrogen plus progestin use (5–24 days/month).

  • d C-CHRT, continuous combined estrogen plus progestin use (25+ days/month).

  • e Ref., referent.

  • f Relative to never users of HRT and adjusted for age, race, study site, and screening mammogram in 2 years before reference (yes/no).

  • g 95% CI does not include 1.0.